English
Back
Open Account
港股窩輪Jenny
wrote a column · Jan 14 10:58

[Warrant Insights] CSPC Pharma’s movements boost warrants! A staggering 53% rise in 2 days—what’s next?

At 10:42 AM on January 14th, $CSPC PHARMA (01093.HK)$
The latest quote is HKD 9.96, with a temporary slight increase of 1.53%, and a turnover reaching HKD 679 million. From a technical perspective,The stock's current support levels are at HKD 8.9 (Support 1) and HKD 8.18 (Support 2), while resistance levels concentrate at HKD 10.32 (Resistance 1) and HKD 11 (Resistance 2). The probability of an upward trend is 51%, with a 5-day volatility of 13.1%. The short-term trend shows a slightly strong oscillation.
From CSPC Pharma's own technical indicators, its RSI has reached 76, indicating an overbought condition. The Williams %R indicator is signaling a sell, and the Stochastic Oscillator also shows a sell signal. The overall technical indicator summary suggests a sell signal with a strength of 10.
At 10:42 AM on January 14th, $CSPC PHARMA (01093.HK)$ The latest quote is HKD 9.96, with a temporary slight increase of 1.53%, and a turnover reaching HKD 679 million. From a technical perspective,The stock's current support levels are at HKD 8.9 (Support 1) and HKD 8.18 (Support 2), while resistance levels concentrate at HKD 10.32 (Resistance 1) and HKD 11 (Resistance 2). The probability of an upward trend is 51%, with a 5-day volatility of 13.1%. The short-term trend shows a slightly strong oscillation. Looking at CSPC Pharma’s own technical indicators, its RSI indicator has reached 76, which indicates an overbought condition. The Williams %R indicator signals a sell, and the Stochastic Oscillator also shows a sell signal. Overall, technical indicators suggest a sell signal, with a signal strength of 10. Yesterday (the 13th), in our [BOC Guest][Share Link: January 13th [Bank of China Guest] Hang Seng Index, Zijin Mining, Jiangxi Copper, CSPC Pharma, Wuxi Bio, China Life]In the segment, Niki Zhu, Director of Bank of China International, commented on CSPC Pharma: Over the past couple of years, innovation in pharmaceuticals in China, along with related licensing deals in terms of quantity and value, has reached recent highs. Investors should pay attention to biopharmaceutical companies like CSPC Pharma and Wuxi Bio. After undergoing a round of adjustments, these stocks have seen price rebounds—for instance, CSPC Pharma has returned near HKD 10. Its previous peak last August and September was HKD 11.49, so there may be potential to challenge that level again in the future. Something worth contemplating...
Yesterday (the 13th), in our [BOC Guest]January 13th [Bank of China Guest] Hang Seng Index, Zijin Mining, Jiangxi Copper, CSPC Pharma, Wuxi Bio, China LifeIn this segment, Niki Zhu, a director at BOC International, commented on CSPC Pharma: Over the past couple of years, China’s innovative drug sector, along with related copyright sales in terms of both volume and value, have reached multi-year highs. Investors should pay more attention to biopharmaceutical companies such as CSPC Pharma, Wuxi Bio, etc. After undergoing a round of adjustments, stock prices of these companies have rebounded. For instance, CSPC Pharma has returned to around 10 yuan, compared to its peak of 11.49 yuan last August and September, so it may potentially challenge previous highs again. Consider broadening your perspective on AI applications, which will help you better understand overall market trends. $Hang Seng Index (800000.HK)$$ZIJIN MINING (02899.HK)$$WUXI BIO (02269.HK)$$CHINA LIFE (02628.HK)$$JIANGXI COPPER (00358.HK)$
Among peers, Wuxi Bio (02269) closed at 39.78 yuan on January 13th, rising by 5.85%. Its technical signal also indicates a 'strong sell' with an RSI of 76, reflecting widespread overbought adjustment pressures within the biopharmaceutical sector. $AKESO (09926.HK)$ On the contrary, Zijin Mining fell by 4.36% to 120.6 yuan, showing a 'buy' technical pattern. This divergence from CSPC Pharma’s trend highlights differences primarily driven by individual stock fundamentals.
Overall, although CSPC Pharma benefited from industry sentiment for a strong single-day performance, significant overheating signs are apparent in its technical aspects. Investors should monitor whether support at 8.90 yuan holds firm and if trading volume continues to cooperate.
Reviewing this recent unusual price movement in CSPC Pharma, the response of its warrants was extremely swift. Recent data clearly demonstrates the linkage effect between them. After the uptrend began on January 9th, relevant warrants saw substantial increases over the following two days. $BP-CSPC@EC2603A.C (17233.HK)$ Two days later, some warrants surged by up to 53%, $BI#CSPC RC2612A.C (65938.HK)$ Others rose by 46%, $UB#CSPC RC2711K.C (63638.HK)$ and $BI-CSPC@EC2604A.C (22986.HK)$ Respectively increasing by 41% and 32%, while the corresponding two-day gain for CSPC Pharma’s underlying stock was only 6.54%. It is evident that the leverage effect of warrants was fully demonstrated in this round of price movements, with warrant gains reaching 6-8 times the rise in the underlying stock, perfectly reflecting the logic of联动 where 'small rises in the underlying lead to big rises in the warrants.'
At 10:42 AM on January 14th, $CSPC PHARMA (01093.HK)$ The latest quote is HKD 9.96, with a temporary slight increase of 1.53%, and a turnover reaching HKD 679 million. From a technical perspective,The stock's current support levels are at HKD 8.9 (Support 1) and HKD 8.18 (Support 2), while resistance levels concentrate at HKD 10.32 (Resistance 1) and HKD 11 (Resistance 2). The probability of an upward trend is 51%, with a 5-day volatility of 13.1%. The short-term trend shows a slightly strong oscillation. Looking at CSPC Pharma’s own technical indicators, its RSI indicator has reached 76, which indicates an overbought condition. The Williams %R indicator signals a sell, and the Stochastic Oscillator also shows a sell signal. Overall, technical indicators suggest a sell signal, with a signal strength of 10. Yesterday (the 13th), in our [BOC Guest][Share Link: January 13th [Bank of China Guest] Hang Seng Index, Zijin Mining, Jiangxi Copper, CSPC Pharma, Wuxi Bio, China Life]In the segment, Niki Zhu, Director of Bank of China International, commented on CSPC Pharma: Over the past couple of years, innovation in pharmaceuticals in China, along with related licensing deals in terms of quantity and value, has reached recent highs. Investors should pay attention to biopharmaceutical companies like CSPC Pharma and Wuxi Bio. After undergoing a round of adjustments, these stocks have seen price rebounds—for instance, CSPC Pharma has returned near HKD 10. Its previous peak last August and September was HKD 11.49, so there may be potential to challenge that level again in the future. Something worth contemplating...
A simple breakdown of the underlying logic: When the underlying stock is pushed higher by positive news, call warrants and bull contracts benefit simultaneously. In situations where market sentiment is positive, the higher the warrant's leverage, the greater the potential increase. Additionally, factors like the distance between the strike price and the current stock price, and changes in implied volatility, are key influences on warrant gains. For example, the best-performing BNP Paribas call warrant (17233) had a strike price of 10.18 yuan, close to CSPC Pharma’s current share price of 9.85 yuan, making it an at-the-money warrant, which more easily appreciates when the underlying stock rises. Meanwhile, its premium and implied volatility were relatively low, further amplifying the upside potential.
Based on the current market conditions, only two of the most cost-effective targets from the warrant pool have been carefully selected for investors' reference.
Top recommendation$BP-CSPC@EC2603A.C (17233.HK)$, this product offers 7.5x leverage with a strike price of 10.18 yuan. Its core advantage lies in having the lowest premium and implied volatility. Given the current overbought correction pressure faced by CSPC Pharma, low-premium products can effectively reduce pullback risks and are more suitable for cautious investors.
For the secondary choice, it is recommended to focus on$BI#CSPC RC2612A.C (65938.HK)$, which offers 4.7x leverage and a recovery price of 8.05 yuan. Not only does it have the lowest premium, but its actual leverage is also relatively high. Moreover, there is sufficient distance between the recovery price and the current support level at 8.9 yuan, providing a relatively ample safety cushion.
At 10:42 AM on January 14th, $CSPC PHARMA (01093.HK)$ The latest quote is HKD 9.96, with a temporary slight increase of 1.53%, and a turnover reaching HKD 679 million. From a technical perspective,The stock's current support levels are at HKD 8.9 (Support 1) and HKD 8.18 (Support 2), while resistance levels concentrate at HKD 10.32 (Resistance 1) and HKD 11 (Resistance 2). The probability of an upward trend is 51%, with a 5-day volatility of 13.1%. The short-term trend shows a slightly strong oscillation. Looking at CSPC Pharma’s own technical indicators, its RSI indicator has reached 76, which indicates an overbought condition. The Williams %R indicator signals a sell, and the Stochastic Oscillator also shows a sell signal. Overall, technical indicators suggest a sell signal, with a signal strength of 10. Yesterday (the 13th), in our [BOC Guest][Share Link: January 13th [Bank of China Guest] Hang Seng Index, Zijin Mining, Jiangxi Copper, CSPC Pharma, Wuxi Bio, China Life]In the segment, Niki Zhu, Director of Bank of China International, commented on CSPC Pharma: Over the past couple of years, innovation in pharmaceuticals in China, along with related licensing deals in terms of quantity and value, has reached recent highs. Investors should pay attention to biopharmaceutical companies like CSPC Pharma and Wuxi Bio. After undergoing a round of adjustments, these stocks have seen price rebounds—for instance, CSPC Pharma has returned near HKD 10. Its previous peak last August and September was HKD 11.49, so there may be potential to challenge that level again in the future. Something worth contemplating...
At 10:42 AM on January 14th, $CSPC PHARMA (01093.HK)$ The latest quote is HKD 9.96, with a temporary slight increase of 1.53%, and a turnover reaching HKD 679 million. From a technical perspective,The stock's current support levels are at HKD 8.9 (Support 1) and HKD 8.18 (Support 2), while resistance levels concentrate at HKD 10.32 (Resistance 1) and HKD 11 (Resistance 2). The probability of an upward trend is 51%, with a 5-day volatility of 13.1%. The short-term trend shows a slightly strong oscillation. Looking at CSPC Pharma’s own technical indicators, its RSI indicator has reached 76, which indicates an overbought condition. The Williams %R indicator signals a sell, and the Stochastic Oscillator also shows a sell signal. Overall, technical indicators suggest a sell signal, with a signal strength of 10. Yesterday (the 13th), in our [BOC Guest][Share Link: January 13th [Bank of China Guest] Hang Seng Index, Zijin Mining, Jiangxi Copper, CSPC Pharma, Wuxi Bio, China Life]In the segment, Niki Zhu, Director of Bank of China International, commented on CSPC Pharma: Over the past couple of years, innovation in pharmaceuticals in China, along with related licensing deals in terms of quantity and value, has reached recent highs. Investors should pay attention to biopharmaceutical companies like CSPC Pharma and Wuxi Bio. After undergoing a round of adjustments, these stocks have seen price rebounds—for instance, CSPC Pharma has returned near HKD 10. Its previous peak last August and September was HKD 11.49, so there may be potential to challenge that level again in the future. Something worth contemplating...
Risk Warning:Intraday fluctuations may be due to short-term speculative trading. Technically, CSPC Pharma has already shown overbought signals. If the underlying stock lacks sustained volume support going forward, its share price could face adjustments, and related warrants might also pull back anytime. Additionally, warrants are high-risk derivatives; always check their real-time premium rates and trading volumes before entering the market. Avoid choosing products with low liquidity or excessively high premiums to prevent potential liquidity risks where timely buying or selling becomes difficult.
What’s your take on whether CSPC Pharma will challenge the previous high of 11.49 yuan? Share your thoughts in the comments section!For more analysis, be sure to follow Jenny's daily updates on "HK Stock Warrants"!
Disclaimer: This article does not constitute any investment advice.
This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We shall not be liable for any loss or damage arising from reliance on the information in this article. Technical analysis merely indicates whether certain technical conditions are met; a comprehensive evaluation of asset performance should incorporate additional data. Trading decisions should not be based solely on the content of this article. Please note that past performance is not indicative of future results.
#Stone Pharmaceutical Group #Hong Kong Stock Market Movements #Warrants Instant Analysis #Intraday Opportunities #Hong Kong Stock Warrants Jenny #Warrants Selection #Warrants Strategy #Derivatives Hedging #Innovative Drug Sector #Hong Kong Stock Investment Reference
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
203K Views
Report
Comments
Write a Comment...
7